MC
SPRY icon

Matisse Capital’s ARS Pharmaceuticals SPRY Stock Holding History

Matisse Capital’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$526K Sell
65,701
-1,528
-2% -$13.1K 0.21% 100
2026
Q1 		$540K Buy
67,229
+11,668
+21% +$112K 0.23% 99
2025
Q4 		$647K Sell
55,561
-2,230
-4% -$21.7K 0.29% 86
2025
Q3 		$581K Buy
57,791
+1,077
+2% +$15.5K 0.26% 97
2025
Q2 		$990K Buy
56,714
+1,000
+2% +$14.4K 0.47% 70
2025
Q1 		$701K Buy
+55,714
New +$670K 0.37% 86

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Matisse Capital's SPRY Position: Q2 2026 in Review

Matisse Capital reduced its ARS Pharmaceuticals (SPRY) stake by 2.3% in Q2 2026, selling an estimated $13.1K and leaving 65,701 shares worth $526K. The position accounts for 0.21% of the portfolio, ranked #100.

Matisse Capital first reported a position in SPRY in Q1 2025 and has held it in 6 quarters since. The position peaked at $990K in Q2 2025. 208 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Matisse Capital held 65,701 shares of ARS Pharmaceuticals worth $526K as of Q2 2026.
  • Matisse Capital sold 1,528 ARS Pharmaceuticals shares in Q2 2026, an estimated $13.1K.
  • ARS Pharmaceuticals made up 0.21% of Matisse Capital's portfolio in Q2 2026, its #100 holding.
  • Matisse Capital first reported a position in ARS Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • Matisse Capital's ARS Pharmaceuticals position peaked at $990K in Q2 2025.
  • 208 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Matisse Capital's 13F filing for Q2 2026, filed 12 Aug 2026.